ClinicalTrials.gg
CompletedNCT01533389STONEUpdated Nov 20, 2013

Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones

A Phase 4 interventional study of Silodosin and Placebo in Ureteral Stone, sponsored by JW Pharmaceutical. Completed at 5 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-11-20.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

A lower ureteral calculus, which measures 5 millimeters and less, may be easily expelled by symptomatic therapy. Actually, it has about a 50% chance of successful expulsion.

However, a complication such as urinary tract infection or hydronephrosis or persistent pain may occur before it is expelled. Thus, it is imperative to minimize the occurrence of complications in the process of expectant treatment and also to reduce the time required to expel calculi.

Pharmacotherapy is to relieve ureteral obstruction and thus to expel urinary calculi easily.

This clinical trial is to evaluate the efficacy of silodosin, a selective α1A-blocker, on calculous expulsion in expectant treatment for patients with lower and mid ureteral calculi.

Read the detailed description

Lower and mid ureteral calculi, accounting for approximately 70% of ureteral calculi, has a high chance of successful treatment thanks to ureteroscopic lithotripsy or extracorporeal shock wave lithotripsy (ESWL)1-3), but at the same time have problems of postprocedural complications and high expenses4). A lower ureteral calculus, which measures 5 millimeters and less, may be easily expelled by symptomatic therapy. Actually, it has about a 50% chance of successful expulsion5). However, a complication such as urinary tract infection or hydronephrosis or persistent pain may occur before it is expelled. Thus, it is imperative to minimize the occurrence of complications in the process of expectant treatment and also to reduce the time required to expel calculi.

It has been recently reported that pharmacotherapy is adhibited to the expulsion of urinary calculi and the relief of pain. The migration of ureteral calculi is influenced by both the calculus and the ureter. In the case of the calculus, size, shape, number and location influence it. In regard to the ureter, it is significantly influenced by the cramp of the ureteral smooth muscle, the edema of the ureteral submucosa, the pain caused by the calculus and the activities of adrenoreceptors6).

Pharmacotherapy is to relieve ureteral obstruction and thus to expel urinary calculi easily. Ureteral obstruction, caused by urinary calculi, obtunds ureteral peristalsis but strengthens ureteral contraction, which may cause urinary retention or regurgitation7-8). In this connection, studies have been conducted as to methods to reduce abnormal urinary reaction caused by urinary calculi and to smoothen uroflow. Currently, hormone drugs including hydroxyprogesterone, prostaglandin synthetase inhibitors, calcium-channel antagonists, α1-blockers and steroid drugs are used to expel urinary calculi and to suppress pain. The guidelines on urinary calculi, drawn up in 2007, recommend using α-blockers as they are superior to other drugs in efficacy9-12).

The drug to be used in this clinical trial, silodosin, was registered under the proprietary name of 'THRUPAS® Capsule 4mg' and is being marketed after being authorized by Korea Food and Drug Administration (FDA), which selectively acts on the α1A-adrenoreceptor.

This clinical trial is to evaluate the efficacy of silodosin, a selective α1A-blocker, on calculous expulsion in expectant treatment for patients with lower and mid ureteral calculi.

02

Conditions studied

  • Ureteral Stone

Browse trials for

03

In context

Ureterolithiasis

84 studies on the registry are indexed under Ureterolithiasis; 19 are open to participants now.

This study's enrollment of 114 is above the median of 101 across 66 interventional studies indexed under Ureterolithiasis.

Browse Ureterolithiasis studies →

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or female patients aged 20 and over
  • Patients having ureteral calculi located mid or lower ureter on abdominal radiograms or excretory urograms or non-enhanced computed tomograms.
  • Patients whose calculi measure 10 millimeters and less.
  • Patients who voluntarily decided to take part in this clinical trial and gave written consent.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not want to undergo expectant treatment
  • Female patients who are pregnant or nursing
  • Patients with febrile urinary tract infection or severe hydronephrosis or ulcerative diseases or hypotension.
  • Patients with severe hepatic dysfunction(e.g. hepatic failure, hepatic cirrhosis, icterus, hepatoma)
  • Patients who take α-blocker or α/β-blockers or calcium-channel blockers or drugs
  • Patients with multiple ureteral calculi
  • Patients whose urinary tracts are anatomically deformed or stenosed
  • Patients who underwent invasive operations on their ureters before
  • Patients whose blood creatinine levels are 2mg/dL and over
  • Patients who are hypersensitive to silodosin
  • Patients who take part in clinical trials other than this one
  • Patients judged to be inappropriate for this clinical trial by investigators
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Silodosin

    8mg QD

    Drug: Silodosin

  • Placebo comparator
    Placebo

    8mg QD

    Drug: Placebo

Interventions

  • Drug: silodosin dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks Arms: Placebo

  • DrugPlacebo

    dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks

06

What researchers measure

Primary outcomes

  1. Expulsion rate of stones

    1 week, 2 weeks, 4 weeks to visit and inspected. (Last visit four weeks) Results when the exhaust is used.

    Time frame: 4 weeks

Secondary outcomes

  1. Stone expulsion time

    Time frame: every 1 week or 2 weeks

  2. Migration distance of stone

    Time frame: every 1 week or 2 weeks

  3. Frequency of administration of oral or injectable analgesics

    Time frame: every 1 week or 2 weeks

  4. Number of cases where subjects visited ER due to uncontrolled pains

    Time frame: every 1 week or 2 weeks

07

Study locations

5 sites
  • NHIC Ilsan Hospital
    Goyang-Si, Gyonggi-Do 410-719, Korea, Republic of
  • Myongji Hospital
    Goyang-Si, Gyonggi-Do 412-270, Korea, Republic of
  • Kangbuk Samsung Medical Center
    Seoul, 110-746, Korea, Republic of
  • Inje Univ. Sanggye Paik Hospital
    Seoul, 139-707, Korea, Republic of
  • Eulji General Hospital
    Seoul, 139-711, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Mar 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2012
First posted
Feb 15, 2012
Start
Oct 2011
Primary completionActual
Mar 2012
CompletionActual
Aug 2012
Last update
Nov 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01533389
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Feb 15, 2012
Start date
Oct 2011
Primary completion
Mar 2012
Completion
Aug 2012
Last update
Nov 20, 2013

Study contacts

Gwan-Joong Joo, Ph.D
principal investigator · Kangbuk Samsung Hospital
Tae-Yoong Jeong, Ph.D
principal investigator · Myongji Hospital
Young-Sik Kim, Ph.D
principal investigator · National Health Insurance Service Ilsan Hospital
Tak-Geun Yoo, Ph.D
principal investigator · Eulji Central Hospital
Jae-Yong Jeong, Ph.D
principal investigator · Inje University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion